How to buy Cingulate Inc stock in Canada

Cingulate Inc is a biotechnology business based in the US. Cingulate Inc shares (CING) are listed on the NASDAQ and all prices are listed in US Dollars.

Its last market close was $4.10 – a decrease of 2.61% over the previous week. Cingulate Inc employs 13 staff and has a market cap (total outstanding shares value) of 0.00.

Our top picks for where to buy Cingulate stock

Buy Cingulate stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Note: The dollar amounts in the table below are in Canadian dollars.

Finder Score for stock trading platforms

To make comparing even easier we came up with the Finder Score. Trading costs, account fees and features across 10+ stock trading platforms and apps are all weighted and scaled to produce a score out of 10. The higher the score the better the platform - simple.

Read the full methodology

Related: Compare the best stock trading platforms in Canada

Cingulate Inc stock price (NASDAQ: CING)

Use our graph to track the performance of CING stocks over time.

Cingulate Inc stocks at a glance

• Key figures

Information last updated 2024-12-19.

Latest market close	$4.10
52-week range	$1.80 - $152.40
50-day moving average more info button	$4.29
200-day moving average more info button	$7.30
Wall St. target price	$48.33
PE ratio more info button	N/A
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$-43.22

Is it a good time to buy Cingulate Inc stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Dive deeper: Our picks for the best stocks to buy right now in Canada

Cingulate Inc price performance over time

Historical closes compared with the close of $4.1 from 2024-12-20

1 week (2024-12-13)	-2.61%
1 month (2024-11-22)	-13.14%
3 months (2024-09-20)	-21.15%
6 months (2024-06-21)	606.90%

1 year (2023-12-22)	97.12%
2 years (2022-12-22)	-98.16%
3 years (2021-12-22)	556.8
5 years (2019-12-19)	N/A

Cingulate Inc financials

Gross profit TTM	$-8,995,280
Return on assets TTM	-104.33%
Return on equity TTM	-273.82%
Profit margin	0%
Book value	$6.82
Market Capitalization more info button	$13.2 million

TTM: trailing 12 months

Cingulate Inc stock dividends

We're not expecting Cingulate Inc to pay a dividend over the next 12 months.

Have Cingulate Inc's stocks ever split?

Cingulate Inc's stocks were split on a 1:12 basis on 8 August 2024 . So if you had owned 12 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Cingulate Inc stocks – just the quantity. However, indirectly, the new 1100% higher stock price could have impacted the market appetite for Cingulate Inc stocks, which in turn could have impacted Cingulate Inc's stock price.

Cingulate Inc stock price volatility

Over the last 12 months, Cingulate Inc's stocks have ranged in value from as little as $1.8001 up to $152.4. A popular way to gauge a stock's volatility is its "beta."

Beta is a measure of a stocks volatility in relation to the market. The market (NASDAQ average) beta is 1, while Cingulate Inc's is -0.907. This would suggest that Cingulate Inc's stocks have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, Cingulate Inc has bucked the trend.

Cingulate Inc overview

Cingulate Inc., a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company's stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults. It also focuses on developing CTx-2103 that is in a formulation stage for the treatment of anxiety. The company was founded in 2012 and is headquartered in Kansas City, Kansas..

Related: New to stock trading? Compare brokers and get tips for investing.

Frequently asked questions

What percentage of Cingulate Inc is owned by insiders or institutions?
Currently 3.3% of Cingulate Inc stocks are held by insiders and 1.557% by institutions. How many people work for Cingulate Inc?
Latest data suggests 13 work at Cingulate Inc. When does the fiscal year end for Cingulate Inc?
Cingulate Inc's fiscal year ends in December. Where is Cingulate Inc based?
Cingulate Inc's address is: 1901 West 47th Place, Kansas City, KS, United States, 66205 What is Cingulate Inc's ISIN number?
Cingulate Inc's international securities identification number is: US17248W1053

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.